Adicet Bio Q1 net loss $30.9M vs prior-year net income; cash $231.6M

Adicet Bio, Inc.

2023-Q1 EPS reported -$0.72

Net loss of $30.9M ($0.72 loss per share) vs net income of $4.6M in Q1 2022.
Cash, cash equivalents and investments $231.6M at March 31, expected to fund ops into H1 2025.
R&D expenses rose to $26.8M from $13.5M YoY, driven by increased CDMO and headcount costs.
Plan to discuss FDA path for ADI-001 pivotal study in Q2 2023; initiate study in Q4 2023.
ADI-270 preclinical data at ASGCT May 18; IND for ADI-925 expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Adicet Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023 was $30.9 million, or a net loss of $0.72 per basic and diluted share, EPS $0.72 per basic and diluted share.

Period: the quarter ended March 31, 2023
Net income: Net loss for the three months ended March 31, 2023 was $30.9 million, or a net loss of $0.72 per basic and diluted share
EPS: $0.72 per basic and diluted share
Result: reported results

Exact text from the filing

Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019685

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.